DaVita (DVA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $3.82
- Estimate
- $3.57
- Surprise
- +6.9%
- Revenue (period 2026-09-30)
- $3.58B
- Score at report (before → after)
- 5.8 → 6.2/10
Revenue source: xbrl.
How the report landed
DaVita (DVA) beat the $3.57 estimate with adjusted EPS of $3.82 — a clear 6.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Sell at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DVA Sell at 6.3/10.
4 of the last 4 quarters beat the estimate; this quarter's +6.9% surprise compares with a +10.0% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Customer: Medicare and Medicare Advantage plans (57.0%)
- Concentration risk — Customer: total government-based programs (68.0%)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $193.31
- Stop
- $180.25
The stock trades at 16.3× trailing but 11.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 2.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
DVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $12.41B
- P/E (fwd)
- 11.3
- P/E (ttm)
- 16.3
- 52-week range
- $101.00–$247.49
- Off 52-week high
- 21.9%
- RSI (14)
- 63
- Volume vs avg
- 2.93×
- Score today
- 6.3/10